Owing to the setting up of new nuclear medicine centers, not only choiceless treatment, such as radioactive iodine therapy, but also an indispensable technique in examination, such as 18-fluorodeoxyglucose positron emission tomography/computed tomography (18FDG PET/CT), has become available to many patients with differentiated thyroid cancer (DTC).The purpose of this review was to analyze numerous studies of new All-Purpose Flour trends in and current recommendations for the use of PET/CT for DTC.Elevated thyroglobulin (TG) levels and negative 131I whole-body scintigraphy data remain a main indication for these techniques.However, PET/CT is also able to change treatment Bladder Health and diagnostic tactics in patients with iodine-sensitive tumors.
The minimum TG level, at which it is clinically appropriate to perform PET/CT, has not so far been determined.Whether there is the need for PET/CT during thyroid-stimulating hormone stimulation remains to be solved.